source
- aTyr Pharma cuts 60% of staff to fund second phase 3 trial of lung disease drug efzofitimodaTyr Pharma announced it will reduce its workforce by about 60%, leaving roughly 20 employees, to reallocate resources toward its lung disease program. The cut follows the company's previous phase…
- Abiomed and Oscor advise correction of Impella catheter introducers due to leakage riskAbiomed and its partner Oscor have issued a notice about a potential leakage in certain catheter introducer sheaths used with Impella heart pumps. The issue involves 14Fr and 23Fr introducer kits,…